Jakafi Launch Going Smoothly, But Incyte Confuses Investors
This article was originally published in The Pink Sheet Daily
Executive Summary
Incyte reported its second quarter results Aug. 2, but failed to communicate its intentions clearly regarding a shift in accounting.
You may also be interested in...
Hang Onto The Launch: Investor Outlook Is Brighter For Some Biotechs
Successful biotech launches like Regeneron’s Eylea, Vertex’s Incivek and others have investors reconsidering the “short the launch” mentality that pervaded the industry a year ago, though no one is throwing caution to the wind.
Hang Onto The Launch: Investor Outlook Is Brighter For Some Biotechs
Successful biotech launches like Regeneron’s Eylea, Vertex’s Incivek and others have investors reconsidering the “short the launch” mentality that pervaded the industry a year ago, though no one is throwing caution to the wind.
Incyte’s Jakafi Gets Additional Claim Based On Patient-Reported Outcomes
Jakafi is the first approved treatment for myelofibrosis, a rare bone marrow cancer, but Incyte will also be able to claim efficacy against the symptoms of the disease thanks to data in labeling from a patient-reported outcomes tool.